-
1 day ago | 
ophthalmologytimes.com | Jason Bacharach |Sheryl Stevenson |Hattie Hayes
Perfluorohexylactane may offer a fast-acting option for dry eye symptom relief, showing measurable benefits within minutes of application, explained Jason Bacharach, MD, who presented findings on the agent’s early efficacy at the 2025 American Society of Cataract and Refractive meeting, held April 25 to 28 in Los Angeles, California.
-
2 days ago | 
optometrytimes.com | AnnMarie Hipsley |Emily Kaiser Maharjan |Sheryl Stevenson |Hattie Hayes
At the 2025 ASCRS meeting in Los Angeles, a concept was shared by AnnMarie Hipsley, DPT, PhD, for optometrists seeking to stay at the forefront of precision ocular care—the Digital Twin. More than a buzzword, a digital twin represents a virtual simulation of a real-world anatomical system, in this case, the human eye.
-
6 days ago | 
ophthalmologytimes.com | Deborah Ristvedt |Sheryl Stevenson |Hattie Hayes
Author(s):,Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians. Deb Ristvedt, DO, moderated a session titled Medications, Lasers, and Lifestyle, highlighting the rapid evolution of glaucoma treatment paradigms at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California.
-
1 week ago | 
ophthalmologytimes.com | Michael Rivers |Hattie Hayes |Sheryl Stevenson
CommentaryVideoMay 6, 2025Author(s):,The first SightLine meeting, held pre-ASCRS, reveals insights on physician-industry relationships, mentorship opportunities, and the practical applications of AI in healthcare.
-
2 weeks ago | 
ophthalmologytimes.com | Inder Singh |Sheryl Stevenson |Hattie Hayes
Inder Paul Singh, MD, glaucoma and anterior segment surgeon from southeastern Wisconsin, presented early data on a novel one-step limited vitrectomy device designed for the removal of symptomatic vitreous opacities (CSVO) in pseudophakic patients.
-
2 weeks ago | 
ophthalmologytimes.com | Hattie Hayes |Sheryl Stevenson |Lisa Nijm
Author(s):,Lisa Nijm, MD, says preoperative osmolarity testing can help clinicians manage patient expectations and improve surgical results. Lisa Nijm, MD, joined the Eye Care Network at the American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting for an on-camera conversation.
-
2 weeks ago | 
optometrytimes.com | Eva Kim |Hattie Hayes |Sheryl Stevenson |Emily Kaiser Maharjan
As the landscape of refractive surgery continues to evolve, many optometrists are seeing increased interest in the EVO implantable collamer lens (ICL) (Staar Surgical) as a primary option—not just for high myopia, but now for low to moderate myopia as well. Eva Kim, MD, cataract and refractive surgeon and uveitis specialist based in Deconfnver, Colorado, spoke on EVO ICL at ASCRS 2025, in Los Angeles, California.
-
2 weeks ago | 
ophthalmologytimes.com | Neda Shamie |Sheryl Stevenson |Hattie Hayes
Neda Shamie, MD, shared her firsthand experience with the new Unity VCS system at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California. “I had the pleasure of working with the Unity VCS system early on, and have done quite a number of cases with the system,” she said. “Several things really were transformative and had a significant 'wow' effect for me.”Shamie emphasized the system’s short learning curve.
-
2 weeks ago | 
modernretina.com | Sheryl Stevenson
As the spring conference season hits its stride, it’s a fitting moment to reflect on how ophthalmic medical meetings have evolved since COVID-19 first upended live events.
-
2 weeks ago | 
ophthalmologytimes.com | Hattie Hayes |Sheryl Stevenson
Author(s):,Patricia Buehler, MD, MPH, presented a poster and two patient films at the ASCRS annual meeting, focused on minimally-invasive blepharoplasty device Ziplyft (Osheru). If you ask Patricia Buehler, MD, MPH, founder and CEO of Osheru, her minimally invasive blepharoplasty device was years—or millennia—in the making.
